Avax Technologies
This article needs additional citations for verification. (August 2022) |
Cancer vaccines | |
Subsidiaries | Genopoietic SA |
---|
Avax Technologies, Inc. is a
AC Vaccine
Method
A tumor sample is removed from a patient, then treated with the hapten 2,4-Dinitrophenol. When reinjected back into the patient, the hapten will cause an enhanced immune response against the cancer cells.[citation needed]
Product Candidates
MVax
Started May 2007. Currently in a Phase III trial for Stage IV Melanoma.
MVax’s Phase II response rate of 35% (CR + PR) in combination with low-dose IL-2 compares favorably to the Phase II results of other melanoma cancer vaccines such as Vical’s Allovectin-7 (11% CR + PR)[2] and BioVex’s OncoVex (28% CR + PR),[3] both of which are given as stand alone therapy.
Due to the
LVax
Started February 2006. Currently in a Phase I/II trial for
OVax
Started April 2008, a Phase I/II trial for ovarian cancer. Encouraging results reported Feb 2016.[6] Median survival was 22.7 months with no treatment-related serious adverse events.[6]
Genopoietic SA
Based in Lyon, France, has a GMP facility that manufactures the vaccines for Avax. The facility is certified by the French government for commercial and clinical vaccine production for the European markets.[1]
See also
Notes
- ^ a b "Avax fact sheet Phase II data" (PDF). Archived from the original (PDF) on 2009-02-06.
- ^ "Allovectin-7 Phase II data". Archived from the original on 2010-03-12.
- ^ "OncoVex Phase II data" (PDF). Archived from the original (PDF) on 2010-10-26. Retrieved 2009-12-21.
- ^ "Enrollment Suspension".
- ^ "December 16, 2009 news". Archived from the original on 2013-05-01.
- ^ a b Advanced Ovarian Cancer Treatment Showing Promise in Clinical Trial. Feb 2016
External links
- Business data for Avax Technologies: